Abraham Jacob

904 total citations · 1 hit paper
32 papers, 602 citations indexed

About

Abraham Jacob is a scholar working on Genetics, Surgery and Pathology and Forensic Medicine. According to data from OpenAlex, Abraham Jacob has authored 32 papers receiving a total of 602 indexed citations (citations by other indexed papers that have themselves been cited), including 15 papers in Genetics, 8 papers in Surgery and 8 papers in Pathology and Forensic Medicine. Recurrent topics in Abraham Jacob's work include Chronic Lymphocytic Leukemia Research (15 papers), Lymphoma Diagnosis and Treatment (8 papers) and Chronic Myeloid Leukemia Treatments (6 papers). Abraham Jacob is often cited by papers focused on Chronic Lymphocytic Leukemia Research (15 papers), Lymphoma Diagnosis and Treatment (8 papers) and Chronic Myeloid Leukemia Treatments (6 papers). Abraham Jacob collaborates with scholars based in Australia, United Kingdom and United States. Abraham Jacob's co-authors include Árpád Illés, Martin Šimkovič, Sean Dolan, Andrzej Pluta, Paolo Ghia, Małgorzata Wach, Daniel Lysák, Wojciech Jurczak, Javier de la Serna and Eric J. Avery and has published in prestigious journals such as Journal of Clinical Oncology, Blood and Journal of Clinical Pathology.

In The Last Decade

Abraham Jacob

29 papers receiving 589 citations

Hit Papers

ASCEND: Phase III, Randomized Trial of Acalabrutinib Vers... 2020 2026 2022 2024 2020 50 100 150 200 250
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. ASCEND: Phase III, Randomized Trial of Acalabrutinib Versus Idelalisib Plus Rituximab or Bendamustine Plus Rituximab in Relapsed or Refractory Chronic Lymphocytic Leukemia
    2020 252 citations Paolo Ghia, Andrzej Pluta et al. Journal of Clinical Oncology profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Abraham Jacob Australia 13 377 298 150 144 104 32 602
Eleonora Russo Italy 13 145 0.4× 193 0.6× 207 1.4× 89 0.6× 143 1.4× 28 555
Karin E. Smedby Sweden 12 164 0.4× 249 0.8× 30 0.2× 106 0.7× 217 2.1× 19 538
M Matucci Cerinic Italy 17 68 0.2× 289 1.0× 207 1.4× 138 1.0× 38 0.4× 47 784
Alberto Floris Italy 16 98 0.3× 172 0.6× 77 0.5× 262 1.8× 48 0.5× 51 854
CY Li United States 10 343 0.9× 317 1.1× 197 1.3× 382 2.7× 164 1.6× 15 717
Marina Stanislav Russia 9 126 0.3× 84 0.3× 179 1.2× 192 1.3× 113 1.1× 20 601
Ho Young Kim South Korea 11 83 0.2× 98 0.3× 97 0.6× 37 0.3× 94 0.9× 34 414
Dennis A. Wong United States 11 236 0.6× 201 0.7× 94 0.6× 221 1.5× 13 0.1× 18 1.2k
Harald Balló Germany 9 698 1.9× 1.1k 3.8× 102 0.7× 131 0.9× 824 7.9× 10 1.3k
Isabel Granada Spain 15 292 0.8× 190 0.6× 463 3.1× 75 0.5× 135 1.3× 53 870

Countries citing papers authored by Abraham Jacob

Since Specialization
Citations

This map shows the geographic impact of Abraham Jacob's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Abraham Jacob with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Abraham Jacob more than expected).

Fields of papers citing papers by Abraham Jacob

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Abraham Jacob. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Abraham Jacob. The network helps show where Abraham Jacob may publish in the future.

Co-authorship network of co-authors of Abraham Jacob

This figure shows the co-authorship network connecting the top 25 collaborators of Abraham Jacob. A scholar is included among the top collaborators of Abraham Jacob based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Abraham Jacob. Abraham Jacob is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Ghia, Paolo, Andrzej Pluta, Małgorzata Wach, et al.. (2022). Acalabrutinib Versus Investigator’s Choice in Relapsed/Refractory Chronic Lymphocytic Leukemia: Final ASCEND Trial Results. HemaSphere. 6(12). e801–e801. 65 indexed citations
2.
Ghia, Paolo, Małgorzata Wach, Daniel Lysák, et al.. (2022). P668: ACALABRUTINIB VS RITUXIMAB PLUS IDELALISIB OR BENDAMUSTINE IN RELAPSED/REFRACTORY CHRONIC LYMPHOCYTIC LEUKEMIA: ASCEND RESULTS AT ~4 YEARS OF FOLLOW-UP. HemaSphere. 6. 566–567. 1 indexed citations
3.
Chakraborty, Priyanka & Abraham Jacob. (2022). Extended chemothromboprophylaxis use in colorectal cancer surgery: a literature review. ANZ Journal of Surgery. 92(7-8). 1644–1650.
4.
Ng, Zi Qin, et al.. (2022). Hepatic metastasis of anal squamous cell carcinoma. BMJ Case Reports. 15(1). e247470–e247470. 1 indexed citations
5.
Jurczak, Wojciech, Andrzej Pluta, Małgorzata Wach, et al.. (2021). Three-Year Follow-up of the Ascend Trial: Acalabrutinib Vs Rituximab Plus Idelalisib or Bendamustine in Relapsed/Refractory Chronic Lymphocytic Leukemia. Blood. 138(Supplement 1). 393–393. 15 indexed citations
6.
Ghia, Paolo, Andrzej Pluta, Małgorzata Wach, et al.. (2020). ASCEND: Phase III, Randomized Trial of Acalabrutinib Versus Idelalisib Plus Rituximab or Bendamustine Plus Rituximab in Relapsed or Refractory Chronic Lymphocytic Leukemia. Journal of Clinical Oncology. 38(25). 2849–2861. 252 indexed citations breakdown →
7.
Ghia, Paolo, Andrzej Pluta, Małgorzata Wach, et al.. (2020). CLL-091: Acalabrutinib Versus Idelalisib Plus Rituximab (IdR) or Bendamustine Plus Rituximab (BR) in Relapsed/Refractory (R/R) Chronic Lymphocytic Leukemia (CLL): ASCEND Final Results. Clinical Lymphoma Myeloma & Leukemia. 20. S220–S221. 1 indexed citations
8.
Ghia, Paolo, Andrzej Pluta, Małgorzata Wach, et al.. (2019). Acalabrutinib vs Rituximab Plus Idelalisib (IdR) or Bendamustine (BR) by Investigator Choice in Relapsed/Refractory (R/R) Chronic Lymphocytic Leukemia: Phase 3 ASCEND Study. Clinical Lymphoma Myeloma & Leukemia. 19. S280–S281. 1 indexed citations
9.
Hillmen, Peter, Christelle Ferrá, José A. García‐Marco, et al.. (2016). Idelalisib in Combination with Bendamustine/rituximab Improves Overall Survival in Patients with Relapsed/refractory Cll: Interim Results of a Phase 3 Randomized Double-Blind Placebo-Controlled Study. Haematologica. 101. 433–433. 2 indexed citations
10.
McCrary, Hilary C., et al.. (2016). The First Reported Case of Recurrent Carcinoid Tumor in the External Auditory Canal. Otology & Neurotology. 38(1). 114–117. 3 indexed citations
11.
Miller, Craig W., et al.. (2015). The Submental Island Flap for Reconstruction of Temporal Bone Defects. Otology & Neurotology. 36(5). 879–885. 18 indexed citations
12.
13.
Assi, Lakhvir K., et al.. (2012). Elevated, combined serum free light chain levels and increased mortality: a 5-year follow-up, UK study. Journal of Clinical Pathology. 65(11). 1036–1042. 35 indexed citations
14.
Holloman, Christopher, et al.. (2011). Melatonin: Can it Stop the Ringing?. Annals of Otology Rhinology & Laryngology. 120(7). 433–440. 28 indexed citations
15.
Jacob, Abraham, et al.. (2010). Cerebral venous sinus thrombosis in a patient with type 1 diabetes in the absence of ketoacidosis. Practical Diabetes International. 27(1). 34–34. 1 indexed citations
16.
Jacob, Abraham, et al.. (2008). The growing burden of injuries and trauma in Alice Springs. Injury. 39. S3–S9. 2 indexed citations
17.
Jacob, Abraham, et al.. (2007). EPIDEMIC OF STAB INJURIES: AN ALICE SPRINGS DILEMMA. ANZ Journal of Surgery. 77(8). 621–625. 18 indexed citations
18.
Otto, Bradley A., Abraham Jacob, Michael J. Klein, & D. Bradley Welling. (2007). Chondromyxoid Fibroma of the Temporal Bone: Case Report and Review of the Literature. Annals of Otology Rhinology & Laryngology. 116(12). 922–927. 20 indexed citations
19.
Jacob, Abraham, Johann Nicholas, Helen Jones, et al.. (2006). Antibody-mediated pure red cell aplasia in a dialysis patient receiving darbepoetin alfa as the sole erythropoietic agent. Nephrology Dialysis Transplantation. 21(10). 2963–2965. 23 indexed citations
20.
Jacob, Abraham, et al.. (1998). Release of clonal block in B cell chronic lymphocytic leukaemia by engagement of co-operative epitopes on CD40. Leukemia Research. 22(4). 379–382. 15 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Eleonora Russo Breakdown of academic impact, for papers by Karin E. Smedby Breakdown of academic impact, for papers by M Matucci Cerinic Breakdown of academic impact, for papers by Alberto Floris Breakdown of academic impact, for papers by CY Li Breakdown of academic impact, for papers by Marina Stanislav Breakdown of academic impact, for papers by Ho Young Kim Breakdown of academic impact, for papers by Dennis A. Wong Breakdown of academic impact, for papers by Harald Balló Breakdown of academic impact, for papers by Isabel Granada
Rankless by CCL
2026